KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Revenue (2016 - 2025)

Jazz Pharmaceuticals has reported Revenue over the past 16 years, most recently at $1.2 billion for Q4 2025.

  • Quarterly Revenue rose 10.09% to $1.2 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.4 billion through Dec 2025, down 17.18% year-over-year, with the annual reading at $4.3 billion for FY2025, 4.88% up from the prior year.
  • Revenue was $1.2 billion for Q4 2025 at Jazz Pharmaceuticals, up from $1.1 billion in the prior quarter.
  • Over five years, Revenue peaked at $1.2 billion in Q4 2025 and troughed at $607.6 million in Q1 2021.
  • The 5-year median for Revenue is $957.3 million (2023), against an average of $948.8 million.
  • Biggest five-year swings in Revenue: surged 39.48% in 2021 and later grew 1.03% in 2024.
  • Tracing JAZZ's Revenue over 5 years: stood at $896.7 million in 2021, then rose by 8.41% to $972.1 million in 2022, then rose by 4.1% to $1.0 billion in 2023, then grew by 7.53% to $1.1 billion in 2024, then increased by 10.09% to $1.2 billion in 2025.
  • According to Business Quant data, Revenue over the past three periods came in at $1.2 billion, $1.1 billion, and $1.0 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.